By comparison, in EPO‐induced AAA, wild‐type mice without hyperlipidemia may manifest AAA upon EPO treatment, which is in line with clinical observations that hyperlipidemia is only a weak risk factor for patients with AAA.[17, 33] Second, elevated blood pressure is consequential in AngII‐induced AAA where infusion of a very high dose of Ang II is mandatory, while EPO treatment exerts no effect on blood pressure in mice. The gene discussed is EPO; the disease is triple-A syndrome.